VEGFA and breast carcinoma: Adding to that, the clinical benefit of bevacizumab, an anti-VEGF-A monoclonal antibody, against breast cancer was unexpectedly limited and showed only an enhancement in the progression free survival (PFS), lacking the improvement in the OS [49].